Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
Update: 2025-10-30
Description
Eli Lilly's experimental weight-loss pill, orforglipron, is poised for a faster FDA approval process, potentially cutting review times from a year to just one or two months. With significant weight loss results and meeting three of the FDA's priority program criteria, Lilly's current GLP-1 medicines, Zepbound and Mounjaro, have seen impressive sales and market demand. Investors and analysts have responded positively to Lilly's strong earnings report, driving its stock price up. However, uncertainties remain, including government efforts to address high prescription drug costs and intense competition in the weight-loss drug market.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
